Monitoring the intrahepatic innate immune responses in chronic HBV patients treated with tenofovir

Completed

• Conditions: HBV; hepatitis B; 10047438

• Registration Number: NL-OMON33915
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 25

Inclusion Criteria

- Male and female older than 18 years, with evidence of a chronic HBV infection
- Indication for antiviral therapy of chronic HBV accorind to current clinical guidelines
- Written informed consent

Exclusion Criteria

- Other causes of liver disease/co-infections
- Other significant comorbidities
- Presence of contra-indications for antiviral therapy with tenofovir

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Outcome measurements<br /><br>Peripheral blood<br /><br>-Frequency, phenotype and function of NK cells,Treg and DCs.<br /><br>-Determination of HBV-specific T cell response<br /><br>-Determination of HBV and proteins in/on NK cells<br /><br><br /><br>Intrahepatic<br /><br>-Frequency, phenotype and function of intrahepatic NK cells and DCs </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>No extra secundary outcome variables</p><br>